BOOT vs FND
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BOOT exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust accounting strength, though the absence of an Altman Z-Score limits distress risk assessment. The company shows impressive profitability and growth, with 18.7% YoY revenue growth and 44.2% earnings growth, supported by strong margins and solid ROE of 18.74%. However, elevated valuation metrics, insider selling, and weakening near-term earnings momentum contrast with bullish analyst sentiment and strong long-term price performance. The stock trades above the Graham Number of $76.71 and below the growth-based intrinsic value of $195.29, suggesting a fair-to-slightly-rich valuation.
FND presents a concerning fundamental profile, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant valuation gap, trading at $51.08 against a Graham Number of $31.07 and an Intrinsic Value of $13.44. The company is experiencing a severe growth crisis, with YoY earnings contracting by 18.2% and revenue growth stalling at 2%. Technical momentum is non-existent (0/100), and a very low quick ratio of 0.30 indicates potential short-term liquidity constraints. While analysts maintain a 'hold' rating with higher targets, the data suggests a company in a structural decline.
Compare Another Pair
Related Comparisons
BOOT vs FND: Head-to-Head Comparison
This page compares Boot Barn Holdings, Inc. (BOOT) and Floor & Decor Holdings, Inc. (FND) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.